Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis

被引:3
|
作者
Zhang, Suo [1 ,2 ]
Chen, Yu-Lan [1 ]
Liu, Cui-Lian [1 ]
Xie, Jing-Yi [1 ]
Sun, Bao-Dong [1 ]
Liu, Dong-Zhou [1 ]
机构
[1] Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Rheumatol & Immunol, Jinan Univ,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Peoples R China
[2] Shenzhen Second Peoples Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
IgA nephropathy; systemic autoimmune myopathies; dermatomyositis; anti- transcription intermediary factor-1 gamma antibody; dermatomyositis-specific antibodies; RENAL INVOLVEMENT; POLYMYOSITIS; AUTOANTIBODIES; SPECTRUM; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; RISK; LOCI;
D O I
10.3389/fimmu.2022.757802
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis characterized by IgA deposits in the mesangial area of glomeruli. Connective tissue disorders are some of the most frequent causes of secondary IgAN. Nevertheless, IgAN rarely occurs in systemic autoimmune myopathies (SAMs). The present case study reports on a 58-year-old patient with dermatomyositis with positive anti-transcription intermediary factor (TIF)-1 gamma antibodies who was diagnosed with IgAN during standard immunosuppressive therapy. Moreover, we have made a systematic review regarding the association of SAMs and IgAN. To the best of the authors' knowledge, this is the first case study describing a patient with anti-TIF1 gamma antibody-positive dermatomyositis who developed IgAN, which demonstrates a potential relationship between anti-TIF1 gamma-positive dermatomyositis and IgAN. It is important for clinicians to be aware of the possibility of renal involvement in patients with SAMs, even in those with anti-TIF1 gamma-positive dermatomyositis.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Pregnancy triggers the onset of anti-transcriptional intermediary factor 1γ antibody-positive dermatomyositis: a case series
    Oya, Kazumasa
    Inoue, Sae
    Saito, Akimasa
    Nakamura, Yoshiyuki
    Ishitsuka, Yosuke
    Fujisawa, Yasuhiro
    Watanabe, Rei
    Taguchi, Shijima
    Fujimoto, Manabu
    Okiyama, Naoko
    RHEUMATOLOGY, 2020, 59 (06) : 1450 - 1451
  • [22] Anti-transcription intermediary factor 1-antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer
    Ogawa, M.
    Sugiura, K.
    Yokota, K.
    Muro, Y.
    Akiyama, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (02) : 373 - 375
  • [23] Association of serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis
    Li, Xi
    Bai, Jingjing
    Li, Siting
    Li, Mengtao
    Zeng, Xiaofeng
    Wang, Qian
    Hu, Chaojun
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 230 - 237
  • [24] Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis
    Wu, Wanlong
    Chen, Jinju
    Zhu, Linling
    Sha, Yaping
    Wang, Kaiwen
    Zhao, Jiangfeng
    Ye, Chunhua
    Ye, Shuang
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 285 - 287
  • [25] Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis
    Kotobuki, Yorihisa
    Tonomura, Kyoko
    Fujimoto, Manabu
    IMMUNOLOGICAL MEDICINE, 2021, 44 (01) : 23 - 29
  • [26] Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report
    Kim, Yoonjoo
    Chung, Chaeuk
    Park, Dongil
    Choi, Song-Yi
    RESPIROLOGY, 2023, 28 : 295 - 296
  • [27] Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report
    Kim, Yoonjoo
    Park, Dongil
    Choi, Song-Yi
    Chung, Chaeuk
    THORACIC CANCER, 2022, 13 (19) : 2808 - 2811
  • [28] Case Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1 Antibody-Positive Dermatomyositis
    Chen, Liang
    Fallavollita, Sabrina
    Sakr, Lama
    Wang, Hangjun
    Pusztaszeri, Marc
    Esfahani, Khashayar
    Pollak, Michael N.
    Hudson, Marie
    Leclair, Valerie
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2025, 28 (01)
  • [29] Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients
    Ogawa-Momohara, M.
    Muro, Y.
    Mitsuma, T.
    Katayama, M.
    Yanaba, K.
    Nara, M.
    Kakeda, M.
    Kono, M.
    Akiyama, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : 990 - 995
  • [30] Anti-SAE Antibody-Positive Dermatomyositis in a Japanese Patient A Case Report and Review of the Literature
    Matsuo, Haruka
    Yanaba, Koichi
    Umezawa, Yoshinori
    Nakagawa, Hidemi
    Muro, Yoshinao
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 (07) : E115 - E116